Keywords: gsk, paxil, cr, cleared, canada, therapeutic, products
GSK's Paxil CR cleared in Canada
Article | 19 January 2004
The Therapeutic Products Directorate of Health Canada has approved GlaxoSmithKline's Paxil CR (paroxetine hydrochloride controlled-release tablets) for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
